SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement…

CATALYST PHARMACEUTICALS, INC. · PREM14A filed May 28, 2026 at 16:56 ET

At the news

BULLISHIMPACT 8/10

PREM14A filed May 28, 2026 at 16:56 ET

Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acquisition by Angelini Pharma at $31.50 per share in cash, a transaction valued at approximately $4.1 billion. The board unanimously recommends the deal, which includes a 28% premium to the 30-day VWAP and follows the resolution of all FIRDAPSE patent litigation with Hetero agreeing not to launch a generic before January 2035.

  • Merger consideration: $31.50 per share in cash (28% premium to 30-day VWAP, 21% premium to unaffected close of $25.94)
  • Total equity value: approximately $4.1 billion
  • Board unanimously recommends voting FOR the merger proposal
  • J.P. Morgan fairness opinion: consideration is fair from a financial point of view

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access